Get the Stockscreener App
0.717
4.29%
0.0295
After Hours:
.72
0.003
+0.42%
Ocugen Inc stock is traded at $0.717, with a volume of 3.17M.
It is up +4.29% in the last 24 hours and up +18.59% over the past month.
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").
See More
Previous Close:
$0.6875
Open:
$0.71
24h Volume:
3.17M
Relative Volume:
0.84
Market Cap:
$190.74M
Revenue:
-
Net Income/Loss:
$-63.08M
P/E Ratio:
-2.6556
EPS:
-0.27
Net Cash Flow:
$-72.53M
1W Performance:
+9.77%
1M Performance:
+18.59%
6M Performance:
-21.22%
1Y Performance:
-42.64%
1-Day Range:
$0.6988
$0.7499
1-Week Range:
$0.65
$0.7499
52-Week Range:
$0.515
$2.06
Ocugen Inc Stock (OCGN) Company Profile
Name
Ocugen Inc
Sector
Industry
Phone
484-328-4701
Address
11 GREAT VALLEY PARKWAY, MALVERN, PA
Compare OCGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OCGN
Ocugen Inc
|
0.717 | 190.74M | 0 | -63.08M | -72.53M | -0.27 |
|
VRTX
Vertex Pharmaceuticals Inc
|
492.42 | 124.91B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
587.85 | 60.05B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
594.65 | 35.88B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.97 | 29.83B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
249.13 | 24.58B | 3.81B | -644.79M | -669.77M | -6.24 |
Ocugen Inc Stock (OCGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-15-24 | Initiated | Maxim Group | Buy |
| Mar-01-23 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Aug-23-22 | Initiated | Mizuho | Buy |
| Jun-15-22 | Resumed | ROTH Capital | Buy |
| Jun-02-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-26-21 | Initiated | Noble Capital Markets | Outperform |
| Jun-11-21 | Downgrade | ROTH Capital | Buy → Neutral |
| May-07-21 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Feb-09-21 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Feb-04-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
View All
Ocugen Inc Stock (OCGN) Latest News
Is Ocugen Inc. (NASDAQ:OCGN) the Best Penny Stock to Invest in Under $1? - Insider Monkey
Ocugen CEO to Present at Prestigious Cell & Gene Meeting on the Mediterranean - MyChesCo
Ocugen to Present at the 2025 Cell & Gene Meeting on the Med - Ocugen
Revolutionary Gene Therapy for Blindness: Ocugen Reveals Commercialization Strategy - Stock Titan
Ocugen Inc. stock falls Tuesday, underperforms market - MarketWatch
OCGN Stock Forecast: 2025-2035 Predictions - Exla Resources
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar - Yahoo Finance
Ocugen Advances OCU200 Clinical Trial Amid Promising Safety Results - MSN
Stock Quote & Chart - Ocugen
Ocugen receives DSMB approval to continue dosing in Phase I trial of OCU200 - Yahoo
Ocugen’s OCU200 advances to next trial phase with safety approval By Investing.com - Investing.com Australia
ROSEN, A LEADING LAW FIRM, Encourages Ocugen, Inc. Investors to Secure Counsel Before Important August 17 Deadline in Securities Class Action – OCGN - Business Wire
OCGN stock touches 52-week low at $0.52 amid market challenges By Investing.com - Investing.com South Africa
OCGN stock touches 52-week low at $0.52 amid market challenges - Investing.com India
Ocugen Advances OCU200 Trial After Safety Board Review -March 18, 2025 at 08:31 am EDT - Marketscreener.com
Ocugen says DSMB approves dosing Cohort 2 in OCU200 clinical trial - TipRanks
Ocugen’s OCU200 advances to next trial phase with safety approval - Investing.com India
Ocugen Announces Approval to Continue Dosing in Phase 1 Trial of OCU200 Following Favorable Safety Review - Nasdaq
Data and Safety Monitoring Board Reviews Cohort 1 Safety Data and Approves Dosing Cohort 2 in the Clinical Trial of OCU200—a Novel Fusion Protein for Diabetic Macular Edema - Ocugen
Data and Safety Monitoring Board Reviews Cohort 1 Safety - GlobeNewswire
Breakthrough Eye Treatment Passes Critical Safety Review: What This Means for 130M Patients - Stock Titan
Ocugen seeks its One Shining Moment - The Healthcare Technology Report.
Breakthrough in Sight? Ocugen’s OCU200 Targets Vision Loss for Millions in New Clinical Trial - MSN
Ocugen Inc. Navigates Uncertainty Amid Potential Shifts in U.S. Fiscal and Tax Policies - MSN
SBI Securities Co. Ltd. Makes New $40,000 Investment in Ocugen, Inc. (NASDAQ:OCGN) - Defense World
Ocugen, Inc. (NASDAQ:OCGN) Shares Acquired by Rhumbline Advisers - Defense World
Equities Analysts Offer Predictions for Ocugen Q1 Earnings - Defense World
FY2029 Earnings Estimate for Ocugen Issued By HC Wainwright - Defense World
Ocugen’s (OCGN) “Buy” Rating Reiterated at HC Wainwright - Defense World
Ocugen Secures ATMP Classification for Gene Therapies Targeting Vision Loss - MSN
Ocugen Stock Lifts Retail Investor Confidence As Q4 Revenue Crushes Estimates - MSN
Ocugen’s Strategic Advancements and Financial Stability Justify Buy Rating - TipRanks
Ocugen Reports 2024 Financial Results and Advances Gene Therapy Programs - MSN
Attention Long-Term Shareholders of Driven Brands Holdings, - GlobeNewswire
Attention Long-Term Shareholders of Driven Brands Holdings, Inc. (NASDAQ: DRVN); Mercury Systems, Inc. (NASDAQ: MRCY); MGP Ingredients, Inc. (NASDAQ: MGPI); and Ocugen, Inc. (NASDAQ: OCGN): Grabar Law Office Investigates Claims on Your Behalf - GlobeNewswire Inc.
Chardan Capital Adjusts Ocugen Price Target to $7 From $6, Maintains Buy Rating -March 06, 2025 at 08:15 am EST - Marketscreener.com
Ocugen, Inc. (NASDAQ:OCGN) Q4 2024 Earnings Call Transcript - Insider Monkey
Ocugen’s Strategic BLA Submissions and Financial Position Support Buy Rating - TipRanks
Beyond The Numbers: 5 Analysts Discuss Ocugen StockOcugen (NASDAQ:OCGN) - Benzinga
Y Intercept Hong Kong Ltd Makes New Investment in Ocugen, Inc. (NASDAQ:OCGN) - Defense World
Ocugen: Q4 Earnings Snapshot - Midland Daily News
Ocugen Inc (OCGN) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Rising Costs - Yahoo Finance
Ocugen Reports Progress in Gene Therapy Trials - TipRanks
Ocugen Provides Business Update with Fourth Quarter and Full Year 2024 Financial Results - GlobeNewswire
Ocugen Inc Earnings Call: Strategic Gains Amid Financial Challenges - TipRanks
Around the Helix: Cell and Gene Therapy Company Updates – March 5, 2025 - CGTLive™
Ocugen Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Ocugen Inc Stock (OCGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.69%
21.50%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):